Diffuse large B-cell lymphoma of the breast: A distinct entity?

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 201-202

  Bierman, P J ^a   Villanueva, M L ^a   Armitage, J O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; RITUXIMAB;

B CELL LYMPHOMA; BREAST CANCER; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM METASTASIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE MIGRATION; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME; TREATMENT OUTCOME;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS;

EID: 38849202374     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm587     Document Type: Editorial

References (15)

1. Ryan G, Martinelli G, Kuper-Hommel M et al. Primary diffuse large B-cell lymphoma of the breast: Prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008; 19: 233-241.
2. Zucca E, Conconi A, Mughal TI et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the tests in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20-27.
3. Zucca E, Conconi A, Pedrinis E et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101: 2489-2495.
4. Pileri SA, Zinzani PL, Gaidano G et al. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma 2003; 44 (Suppl 3): S21-S26.
5. Pals ST, de Gorter DJJ, Spaargaren M. Lymphoma dissemination: The other face of lymphocyte homing. Blood 2007; 110: 3102-3111.
6. van Besien K, Ha CS, Murphy S et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma, Blood 199a; 91: 1178-1184.
7. Hollender A, Kvaloy S, Nome O et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: A risk model. Ann Oncol 2002; 13: 1099-1107.
8. Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's ymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients. Ann Oncol 2000; 11: 685-690.
9. Ganjoo K, Advani R, Mariappan MR et al. Non-Hodgkin lymphoma of the breast. Cancer 2007; 110: 25-30.
10. Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2005; 19: 597-609.
11. Miller TP, Spier CM, Rimsza L. Diffuse aggressive histologies at non-Hodgkin lymphoma: Treatment and biology of limited disease. Semin Hematol 2006; 43: 207-212.
12. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: What has changed over the past 10 years?. Br J Haematol 2006; 136: 521-538.
13. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110: 29-34.
14. Fu K, Perr KD, Smith LM et al. Effect of addition of rituximab to CHOP on survival of patients in both the GCB and non-GCB subgroups of diffuse large B-cell lymphoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(18 Suppl): (Abstr 8040).
15. Lenz G, Wright G, Sandeep D et al. Gene expression signatures predict overall survival in diffuse large B-cell lymphoma treated with rituximab and CHOP-like chemotherapy. Blood 2007; 110: 209a (Abstr 348).